Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RUBY: REGN910-3 (Nesvacumab + Aflibercept) in Diabetic Macular Edema
NCT02712008Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Mar 2016
- Primary completion
- Jul 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nesvacumab in diabetic macular edema (DME) (8 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Change From Baseline in Best Corrected Visual Acuity (BCVA) Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at 36 weeks. Started Mar 2016; status: completed.
02
Drugs
nesvacumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT02712008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02712008.